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ABSTRACT 
  
Background. One explanation for the relationship between vitamin D and 
cardiovascular disease (CVD) mortality could be related to altered serum lipids. This 
study aimed to determine the association between 25OHD and serum lipid 
concentrations in healthy, older adults. 
 Methods. Serum lipid panels and 25OHD concentrations were obtained on 190 
adults (median age 67 years) after a 12-hour overnight fast. 25OHD was measured by 
the DiaSorin Liason system. Subjects were stratified by 25OHD concentrations: <20.0 
ng/mL, 20.0-29.9 ng/mL, 30.0-39.9 ng/mL and ≥40 ng/mL. One-way ANOVA was used to 
observe unadjusted differences and Student’s t-tests were used to determine 
differences between groups. Multiple regression analyses were performed to 
determine the ability of 25OHD to predict serum lipid concentrations when accounting 
for BMI, sex, age, and statin use. Stepwise regression analyses were used to establish 
the best prediction model for each outcome. 
 Results. There was a significant relationship between 25OHD and BMI (p<0.001), 
glucose (p=0.042), TG (p=0.020), TC (p<0.001), LDL (p<0.001) and the TC:HDL ratio 
(p<0.001), but not for blood pressure, HDL, or TG:HDL ratio. When comparing subjects 
with 25OHD  ≥40.0 ng/mL to those with <20 ng/mL, those in the highest group had a 
significantly lower BMI (26.1 ± 0.7 and 29.9 ± 0.8 kg/m2), TG (100.9 ± 7.8 and 130.4 ± 
9.5 mg/dL), TC (182.7 ± 5.2 and 217.4 ± 6.3 mg/dL), LDL (100.3 ± 4.5 and 131.2 ± 5.4 
mg/dL), and calcium (9.67 ± 0.05 and 9.50 ± 0.06 mg/dL) concentrations, and had 
significantly lower TC:HDL  (3.09 ± 0.15 and 4.15 ± 0.08) and TG:HDL (1.79 ± 0.22 and 
2.56 ± 0.27) ratios.  
 When adjusting for confounders, the relationship between 25OHD and TC 
(p<0.001) and LDL (p<0.001) remained significant, but that between TC:HDL and 
TG:HDL did not. When a stepwise regression analysis was performed to determine the 
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best model for predicting serum lipid parameters, each 10 ng/mL increase in 25OHD 
predicted a statistically significant 6.72 mg/dL decline in TC (p<0.001) and 5.55 mg/dL 
decline in LDL (p<0.001). 
 Conclusion. 25OHD status is associated with favorable concentrations of TG, TC, 
LDL and lipid ratios in older adults. When adjusting for confounders, this relationship 
remains for TC and LDL. Altered lipid metabolism may help explain the association 
between vitamin D and CVD mortality.
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CHAPTER I 
 INTRODUCTION: THESIS FORMATTING 
 This thesis will begin with a review of the pertinent literature pertaining to 
vitamin D and blood lipid parameters. Background will be provided regarding vitamin D 
metabolism, followed by an overview of classical functions of vitamin D and ending 
with a synopsis of vitamin D in relation to cardiovascular disease and, specifically, blood 
lipid parameters. After the literature review, a prepared manuscript for publication will 
be presented; this manuscript will meet criteria for submission the Journal of Nutrition. 
This manuscript will begin with an abstract followed by an introduction, methods 
section, results of the study and end with a discussion of findings.  
  
2 
 
CHAPTER II 
REVIEW OF LITERATURE 
Introduction 
Vitamin D is a fat-soluble vitamin that functions as a steroid hormone and can 
be obtained from the diet or from endogenous synthesis in the skin with exposure to 
ultra-violet B (UVB) light. Traditionally, we think of vitamin D for its role in calcium and 
phosphorus homeostasis. However, vitamin D is a prehormone with numerous 
extraskeletal roles, and interest in these non-traditional functions is increasingly 
popular in the literature. In particular, the role of vitamin D in chronic diseases is 
currently an area of unremitting attention; one emerging area of vitamin D research is 
the relevance of vitamin D status to cardiovascular disease, the number one cause of 
mortality in the United States (1). This literature review aims to summarize the 
metabolism and function of vitamin D, give an overview of its classical functions, 
introduce novel applications of its use and give an in-depth review of vitamin D as it 
pertains to cardiovascular disease and, specifically, serum lipid concentrations. 
 
Vitamin D 
Vitamin D Metabolism 
Vitamin D is a steroid hormone that is unique in comparison to other vitamins in 
that it can be synthesized endogenously by the skin photochemically from 7-
dehydrocholesterol. 7-dehydrocholesterol is a sterol produced by animals and is 
located in the skin, with the highest concentrations in the stratum basale and stratum 
spinosum. When skin is exposed to radiation in the optimum wavelengths for the 
production of vitamin D, between 290 and 320 nanometers, 7-dehydrocholesterol in 
the dermis and epidermis is converted to previtamin D (2–4). Previtamin D is 
subsequently converted to either vitamin D3 (cholecalciferol) via three heat-dependent 
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isomerization reactions, or undergoes further photoisomerization to non-vitamin D 
molecules, tachysterol, lumisterol, or toxisterol. Toxic concentrations of vitamin D 
cannot be reached due to synthesis in the skin. Maximum vitamin D synthesis occurs in 
a few minutes of optimum wavelength UVB rays on light skin; at midday at an 
appropriate zenith angle for vitamin D synthesis, optimum levels may be reached with 
full body exposure in as little as one minute and the initiation of skin damage occurs 
after approximately 15 minutes (5). Further exposure initiates photodegradation and 
increases the concentration of the aforementioned non-vitamin D molecules, but does 
not increase vitamin D concentrations despite linear increases in DNA damage (3,4). 
The amount of vitamin D synthesized in the skin depends on initial 7-
dehydrochoelsterol concentrations, skin pigmentation, season, time of day, latitude, 
sunscreen use, amount of skin exposed, and age (3,6).  
Vitamin D may also be obtained from the diet naturally in a small number of 
foods (e.g.  fatty fish), fortified into food products (e.g. dairy products), or obtained in a 
supplement form (7). Similarly to other fat-soluble vitamins, vitamin D is absorbed with 
dietary fat in the small intestine and then transported into the lymphatic system in 
chylomicrons. Supplemental forms of vitamin D can also be found in the plant- or 
fungal-derived form, vitamin D2 (ergocalciferol), which was previously shown to be less 
effective at increasing serum levels of 25OHD (the storage form of vitamin D) (8–10), 
but this difference in efficacy has recently been challenged (11–13). From this point 
onward, both vitamin D2 and vitamin D3 will be referred to collectively as vitamin D 
unless otherwise specified. Regardless of its origin, vitamin D is transported via the 
vitamin D binding protein (DBP) to the liver, where the first hydroxylation to 25OHD 
(calcidiol) occurs. This reaction is catalyzed by one of several cytochrome p450 enzymes 
(14,15). Calcidiol enters the circulation bound primarily to DBP; it has a half-life of 
approximately 15 days and is the most commonly used and appropriate measurement 
of vitamin D status (16).  
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The second hydroxylation reaction occurs primarily in the kidney and converts 
calcidiol to the physiologically active 1,25(OH)2D (calcitriol), or activated vitamin D (17). 
The calcidiol-DBP complex enters the kidney from the plasma through glomerular 
filtration and subsequent uptake occurs in the proximal tubular cells by megalin and 
cubilin via endocytosis (18). The enzyme CYP27B1 (1αOHase) is primarily responsible 
for catalyzing the second hydroxylation of 25OHD to 1,25(OH)2D in the kidney. Contrary 
to the first hydroxylation reaction in the liver, the activity of this enzyme, thus 
activation of calcidiol to calcitriol, is under tight regulation by the parathyroid hormone 
(PTH), calcium, phosphate, calcitonin, and fibroblast growth factor 23. 1αOHase is also 
self-regulated by negative feedback, preventing excessive formation of the 
physiologically active calcitriol. Following activation, calcitriol is then transported in the 
circulation bound to DBP and acts on tissues displaying the vitamin D receptor (VDR). 
Calcitriol is a greater affinity ligand for VDR than is the calcidiol precursor. However, 
studies done on CYP27B1 knockout mice conclude that calcidiol also has direct gene 
regulatory function and acts synergistically with calcitriol (19,20). The half-life of 
calcitriol is 10-24 hours (4). Both calcidiol and calcitriol may be inactivated by CYP24A1, 
which 24-hydroxylates the molecules and subsequent catabolism deems them water-
soluble, allowing for excretion in the urine (15). 
Measuring Vitamin D  
Measuring calcidiol is more appropriate than calcitriol for assessing vitamin D 
status because calcitriol has a short half-life, it does not increase directly with intake or 
synthesis from 7-dehydrocholesterol, and concentrations of calcitriol may be 
maintained even in the instance of vitamin D insufficiency. Relatively high variability in 
vitamin D values can be problematic when comparing concentrations across studies, so 
it is important to consider the method of measurement and to understand the benefits 
and limitations of each (21). First, it should be noted whether serum or plasma is used 
for reading vitamin D levels, as plasma samples read approximately 5 ng/mL higher 
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than serum levels (22). Different assay types include liquid chromatography/mass 
spectrometry, high performance liquid chromatography, radioactive immunoassay, and 
chemiluminesence protein-binding assays; differences in measurement may occur 
between assay types, especially when vitamin D2 is supplemented as opposed to D3 
(23,24). The LIAISON 25(OH)D chemiluminescence protein-binding assay has been 
validated by several different research groups as an appropriate measurement method 
(22,23,25). 
Vitamin D Intake and Status 
The optimal range of vitamin D concentrations to attain the greatest benefits to 
health is an ongoing debate (26,27). In 2011, the Institute of Medicine (IOM) (27) and 
the Endocrinology Society (26) both published reports addressing the issue and, 
although there were similarities between the two, both made different conclusions 
relating to the classification of vitamin D deficiency. The IOM stated that a vitamin D 
concentration of 20 ng/mL is adequate for bone health for most people and they did 
not deem the evidence for the many non-traditional roles of vitamin D sufficient 
enough to support higher recommendations at the time the report was published (27). 
Conversely, the Endocrine Society recommended a vitamin D concentration of at least 
30 ng/mL and deemed the evidence supportive of vitamin D for the prevention of falls 
and suppression of PTH concentrations, which are associated with increased mortality 
and heart failure (26,28,29). The American Dietetic Association (now called the 
Academy of Nutrition and Dietetics) supported the IOM guideline of a vitamin D 
concentration ≥20 ng/mL to provide optimum bone health (30). Some researchers who 
work closely with vitamin D stand behind a more liberal optimum range of 40-60 
ng/mL, but this is not adopted or universally accepted by all (31,32). Evidence to 
support either further benefits and/or potentially negative consequences of vitamin D 
concentrations higher than traditionally recommended is necessary. 
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Vitamin D optimization enables calcium absorption but increasing 
concentrations of 25OHD does not cause an increase in calcium uptake until toxic levels 
(100-150 ng/mL) are reached; levels of calcidiol in the blood do not correspond to 
concentrations of the physiologically active calcitriol, and this active form can 
potentially be elevated due to vitamin D insufficiency. Both the IOM and the Endocrine 
Society stood behind an upper limit of 25OHD of 100 ng/mL for safety from vitamin D 
intoxication (26,27), but some vitamin D researchers trust that there are no adverse 
effects with calcidiol levels up to 150 ng/mL (6). To achieve 100 ng/mL, upwards of 
10,000 IU/day would need to be consumed for a length of time. A general rule of 
thumb is that regular intake of 100 IU will increase blood levels by approximately 1 
ng/mL, although the rate of rise in blood concentrations is dependent on the initial 
blood values as well as other characteristics and factors that can affect vitamin D 
metabolism (e.g. kidney function (33) and amount of adipose tissue(13)). Those 
deficient in vitamin D have a faster rise in calcidiol concentrations with 
supplementation than those with adequate levels before supplementation. Blood 
concentrations of vitamin D in overweight or obese individuals respond less quickly to 
supplementation due to sequestration in adipocytes (34,35). 
There has been a lot of recent discussion about the optimal range for vitamin D 
status, the incidence of vitamin D deficiency, and the effects of vitamin D insufficiency. 
Disagreements related to optimum blood concentrations lead to arguments about 
appropriate dosages, as levels required for bone health are lower than those shown to 
have physiologically significant effects on novel discoveries of vitamin D action. The 
IOM reevaluated the literature pertaining to calcium and vitamin D levels and 
concluded that vitamin D status is not a major problem and maintained the Estimated 
Average Requirement (EAR) of 400 IU/day for most people one year and older and a 
Recommended Dietary Allowance (RDA) of 600 IU/day for most people over the age of 
one year, except for those >70 years old, who were given an RDA of 800 IU/day (27). An 
upper limit of 4,000 IU/day for healthy adults was established by both committees but 
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the Task Force for the Endocrine Society guideline report recommended higher levels 
(up to 10,000 IU/day) for adults who are deficient or at risk for deficiency (26,27). 
Both the IOM and Endocrine Society acknowledged that several factors affect 
vitamin D status aside from dietary intake. First and foremost, the amount of UVB 
exposure has a large impact on vitamin D status, as synthesis from the skin can 
contribute to serum concentrations to a greater extent than amounts obtained from 
diet, especially from food alone. As expected, locations farther from the equator have a 
higher incidence of vitamin D deficiency, particularly in the winter months (6). In 
addition, vitamin D is only synthesized in the midday hours, when UVB concentrations 
in the appropriate wavelength are highest. Even in areas with adequate UVB radiation 
in the optimum wavelength, vitamin D deficiency is more prominent in the frail, 
bedridden, and elderly because of insufficient sun exposure and/or reduced capacity 
for synthesis (6,26,27). 
Certain changes in metabolic function are associated with a lower vitamin D 
status, but whether or not certain populations should have increased levels of vitamin 
D intake is another point of contention (26,27,36). Most recognized is an increased 
need for vitamin D in the older population due to less time outdoors, less dairy 
consumption, and the decreased capacity to synthesize vitamin D from 7-
dehydrocholesterol in the skin (6,26,37). This issue is addressed with the increased RDA 
value of vitamin D for those >70 years old, yet vitamin D status and intake are still 
lower in this population (7,27,36,38). The Endocrine Society also acknowledges a 
benefit of having a vitamin D concentration above 30 ng/mL for the prevention of falls 
in this group (26,39). 
Other diseases and conditions are associated with metabolic changes that may 
impact or may be impacted by insufficient vitamin D. Chronic kidney diseases or 
impaired renal function impact the uptake and subsequent activation of calcidiol to 
calcitriol, thus implicating those with kidney disease or those at risk for kidney 
problems (e.g., diabetics) with a higher risk for insufficient calcidiol and calcitriol 
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concentrations (6,33). Obese individuals are at a greater risk for vitamin D deficiency, 
potentially due to its sequestration in the adipose tissue (35,40–42). On the other hand, 
adipocytes contain VDR and the ability to synthesize 1αOHase and may instead regulate 
adipocyte differentiation and metabolism by inhibiting or promoting adipogenesis via 
VDR. The underlying mechanisms for either explanation for the association between 
decreased vitamin D and increased adipose tissue mass have not been elucidated 
(42,43). Consequently, lower vitamin D status is associated with several chronic disease 
profiles linked with obesity, such as the metabolic syndrome, cardiovascular disease, 
diabetes and certain types of cancer. More detail on these associations and potential 
underlying mechanisms will be provided in the subsequent sections on the mechanisms 
of action for vitamin D and novel revelations about its use. 
Classical Mechanisms of Vitamin D 
Vitamin D conveys biological activity by binding to VDR, primarily in the nuclei of 
target cells (44). When calcitriol binds to VDR in the nucleus, it activates VDR and, 
together with a retinoid X receptor, binds to DNA at the Vitamin D Response Element 
(VDRE), working as a ligand-activated transcription factor within the promoter region of 
genes to activate or repress transcription of a gene by influencing the rate of 
transcription (45). This process is well known for the induction of calcium channel 
transporters, allowing for active transport of calcium in the intestinal enterocytes in the 
case of lower calcium intake. Additionally, calbindin-D9k and the basolateral transient 
receptor potential vanilloid type 6 (TRPV6) membrane calcium pump are up-regulated 
by vitamin D to promote transcellular transport of calcium into the intestinal epithelia. 
Expression of these proteins does not necessarily correlate with intestinal calcium 
absorption, but transcellular transport of calcium is influenced by calcitriol, suggesting 
that calcitriol regulates other steps in the process of calcium absorption aside from 
transcription of the calbindin and TRPV6 genes (46).  
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In short, calcitriol enables the maintenance of blood calcium concentrations 
within the normal range. When blood calcium concentrations decline, the parathyroid 
gland senses the change and induces the secretion of PTH. PTH influences CYP27B1 and 
thus activation of calcidiol to calcitriol in the kidney, and its presence in the small 
intestine increases absorption of dietary calcium. Calcitriol also acts with PTH to 
activate osteoclasts, promoting bone resorption and freeing calcium to maintain 
homeostasis. Finally, calcitriol acts to facilitate reabsorption of calcium in the kidney. 
The final activation of vitamin D is suppressed by the both the presence of calcitriol, 
which itself inactivates 1αOHase, and restored phosphate concentrations, which halts 
further production of PTH. Fibroblast growth factor 23, which is released from the bone 
in response to an increase in phosphorus and calcitriol concentrations, suppresses the 
activation of calcidiol in the kidney and also induces CYP24A1, an enzyme that converts 
calcidiol and calcitriol to water soluble forms for excretion via 24-hydroxylation 
(6,15,47). 
This relationship between vitamin D and calcium absorption has been well 
described. Consequently, calcitriol is primarily known for its activity in calcium and 
phosphorus homeostasis, and the use of vitamin D supplementation to improve bone 
density is well established (48). Modern views on vitamin D implicate its association in 
many other disease states and conditions, but because of the tight association with 
vitamin D and calcium and their concurrent use in interventions, it is sometimes 
difficult to assess whether or not the optimization of calcium homeostasis or vitamin D 
itself is conveying the effects (6,47). 
Novel Actions of Vitamin D 
VDRs are found in tissues fairly ubiquitously throughout the body and the 
activating enzyme, 1αOHase, is present in several extrarenal tissues, including the 
brain, prostate, breast, vasculature, and immune cells, alluding to the modernly viewed 
role of vitamin D in paracrine and autocrine functions outside of bone health (49–52). 
10 
 
In addition, megalin, a protein with several functions including uptake of vitamins 
(including vitamin D) and their binding proteins, is present in many tissues and organs 
implicated in disease states associated with vitamin D deficiency (53,54) and likely 
provides a mechanism for targeting vitamin D to specific cells and tissues. 
Fall Prevention 
Closely related to skeletal health is the role of vitamin D in muscular function 
and fall prevention. Muscular contractions perpetuate the process and the 
maintenance of bone health by providing a stimulus for adaptation (55). Aside from the 
benefits to bone density, muscle weakness and sarcopenia are also associated with 
increased PTH and low vitamin D concentrations, and supplementation with vitamin D 
improves functional ability in frail, elderly adults (39,56). The recognition that changes 
in walking pattern and muscle function emerge with low vitamin D status attributed to 
the recommendation that older adults (>70 years old) have a higher vitamin D intake 
(26). 
Authors conducting a meta-analysis observed a benefit of vitamin D 
supplementation on muscular function, size, and/or performance for 7 of 16 
randomized-controlled trials, but many studies included in the analysis were not set up 
specifically for this purpose and presented these parameters as secondary outcomes 
(57). A recent study by Close and colleagues (58) supplementing young club level 
athletes with a placebo, 20,000 IU/week, or 40,000 IU/week of vitamin D for 12 weeks 
did not observe an improvement in physical function. However, only approximately half 
of the participants included were vitamin D deficient and the population started with 
good physical performance, so it would be more difficult to see an improvement in this 
population than with a vitamin D deficient group because of the lowered potential for 
gains in performance. 
A meta-analysis by Bischoff-Ferrari (59) aiming to look at the efficacy of 
supplemental cholecalciferol on preventing fractures concluded that 700-800 IU/day, 
achieving concentrations of approximately 24 ng/mL, reduces the risk of fracture. The 
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same analysis found a reduced relative risk of falls by 19% with supplemental doses of 
700-1000 IU vitamin D/day. Pfeifer and colleagues (60) supplemented 242 older adults 
with 500 mg calcium or 500 mg calcium plus 400 IU cholecalciferol at breakfast and 
dinner for one year and found significant improvements in muscular strength, 
improved up-and-go test time, and decreased body sway and falls in the calcium plus 
vitamin D group. Moreira-Pfrimer et al (61) observed an improvement in muscular 
strength in institutionalized elderly people after supplementation of calcium and 
cholecalciferol, independent of physical activity. To separate the effects of vitamin D 
from calcium, Gloth et al. (56) supplemented frail, elderly people who were deficient in 
vitamin D (<15 ng/mL) with vitamin D alone and noticed gains in functional 
improvement in those increasing calcidiol concentrations by at least 3 ng/mL. 
Mortality 
Several large, epidemiological studies and meta-analyses have found 
associations between low vitamin D status and an increased risk for overall premature 
mortality (6,36,52,62). Specifically, a recent analysis of the associations between all-
cause mortality and cause-specific mortality found strong associations between vitamin 
D status and mortality from all causes, cardiovascular disease, cancer, and respiratory 
diseases in a middle-aged, German population (63). Another recent meta-analysis by 
Zittermann and colleagues (62) found a relative risk of 0.71 for the highest compared to 
the lowest quintile of vitamin D status and provided further evidence for a greater 
benefit with a vitamin D status in the 40-60 ng/mL range. The reasons behind a higher 
risk for mortality with inadequate vitamin D status haven’t been completely elucidated 
and are multifactorial. Studies on mice without VDR can provide a lot of insight into the 
many metabolic disturbances related to vitamin D, but human studies with direct 
evidence are just beginning to appear (64).  
Immunity and Inflammation 
Several cell types in both the innate and adaptive immune system display VDR 
and can synthesize 1αOHase, alluding to a role of vitamin D in immunity (50,65,66). 
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Calcitriol is an immunoregulatory hormone with well documented inhibitory effects of 
macrophages and dendritic cells and has a beneficial role in Th1 cell mediated 
autoimmune disease (e.g., type I diabetes and lupus). Additionally, Boonstra et al. (67) 
demonstrated that calcitriol affects T helper (Th) cells by inhibiting Th1, cells 
overproduced in autoimmune diseases, and enhancing Th2 cell production. Disease-
activated macrophages have the ability to produce calcitriol in quantities sufficient to 
be detected in circulation (68) and likely convey local immunoregulatory function (49). 
Obesity 
Vitamin D levels are inversely correlated with adiposity (34,35,40,42,69). 
Specifically, those with low vitamin D are at a greater risk for subcutaneous and visceral 
adiposity associated with metabolic syndrome.  Because many studies involving vitamin 
D supplementation also include calcium, it is difficult to differentiate whether or not 
conditions related to increased adiposity are associated with vitamin D, calcium, or 
both. Higher intakes of calcium are inversely related to body mass, and 
supplementation with calcium slightly decreases adiposity (70). Additionally, fat mass 
should be taken into consideration when determining appropriate dosages of vitamin 
D, as body mass index (BMI) is inversely associated with the rate of increase in calcidiol 
concentrations following supplementation (34).   
Intervention studies aimed at evaluating the effects of vitamin D 
supplementation on obesity and its metabolic effects have not fully supported a 
beneficial role of vitamin D on body weight (71). One study by Salehpour et al. (72) 
observed a decrease in fat mass after supplementing overweight and obese women 
with 1,000 IU vitamin D/day for 12 weeks, but did not see a change in body weight or 
waist circumference. Wamberg et al. (73) conducted a double-blind randomized-
controlled trial (RCT) on 52 overweight, vitamin D-deficient adults and found no 
beneficial effect of 7,000 IU vitamin D/day for 26 weeks on insulin resistance, blood 
pressure, plasma lipids or inflammatory markers. A recent double-blind RCT did not 
observe an effect of vitamin D on weight loss, but showed a greater increase in calcidiol 
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concentrations in the weight loss plus vitamin D group than with either weight loss or 
vitamin D supplementation alone, and concluded that vitamin D supplementation may 
attenuate the loss of bone mineral content associated with weight loss (74).  
The association between adiposity and low vitamin D should be considered 
when reflecting upon associations and potential cause-and-effect relationships 
between vitamin D and diseases associated with increased adiposity (e. g., certain types 
of cancer, diabetes, and cardiovascular disease). 
Cancer 
The genes related to calcium and phosphorus homeostasis that are controlled 
by vitamin D are only a few of the 200+ genes regulated by vitamin D; among these are 
genes related to the cell cycle. There is an association between distance from the 
equator and the incidence of cancer and, specifically, an inverse relationship between 
vitamin D concentrations and several cancer types. Tissues implicated in cancer types 
associated with vitamin D often display both VDR and 1αOHase, such as the breast, 
colon, and prostate (6). Additionally, megalin, an endocytotic receptor protein which 
can internalize the vitamin D-DBP complex, is expressed in some of these tissues (54). A 
clinical study supplementing calcium plus vitamin D showed a reduced risk for all 
cancers of approximately 60% (75) and vitamin D may be a protective, low-cost 
alternative to cancer prevention (76). 
 Calcitriol is known to inhibit melanoma cell proliferation and stimulates 
myeloid leukemia cell differentiation. It may also inhibit endometrial cancer by halting 
cell growth (77). Vitamin D has also proven beneficial in human skin cells, even though 
the sunlight associated with vitamin D synthesis has been thought to be harmful in the 
same effect (78,79). Vitamin D is associated with non-melanoma skin cancer, which is 
easily detectable and treatable, but not with melanoma, the more detrimental type of 
skin cancer (80).  In opposition of vitamin D for the prevention of cancer risk, a recent 
observational study did not conclude that vitamin D was a useful measure to predict 
breast cancer risk and found BMI to be the only factor measured with a significant 
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influence (81). Definitive intervention studies and underlying mechanisms for the role 
of vitamin D in cancer are ongoing but inconclusive at this time.  
Diabetes 
Low concentrations of vitamin D are more prevalent in diabetics, and diabetics 
with inadequate vitamin D stores are twice as likely to develop cardiovascular disease 
(82). Diabetes and its associated insulin resistance and increased adiposity are strong 
risk factors for CVD; in addition, the effects of vitamin D on insulin secretion and insulin 
sensitivity may indirectly affect lipid metabolism. Calcidiol levels are inversely 
associated with fasting glucose levels, glucose tolerance and hemoglobin A1c (HgA1c) 
concentrations in adults and in children (69,83–85). In addition, 1αOHase is expressed 
in both adipocytes and the insulin-producing pancreatic β-cells (49,50), and insufficient 
concentrations of vitamin D are associated with decreased insulin sensitivity (85,86) 
and pancreatic beta cell dysfunction (86).  
Direct supplementation with the active calcitriol showed beneficial effects on 
glucose clearance, glucose tolerance and insulin secretion in rats (87). A recent study by 
Breslavsky et al. (84), however, did not find a change in glucose homeostasis in a small 
group of diabetic patients supplemented with 1000 IU vitamin D/day for 12 months 
compared to those receiving a placebo. Further opposition to this effect in vivo was 
shown with a statistically significant increase in HgA1c levels after one year of vitamin D 
supplementation in one study, but the increase was not clinically meaningful (88).  
BMI (as it relates to adiposity) and inflammatory markers are strong predictors 
of insulin sensitivity, and both are also associated with vitamin D, so it is difficult to 
differentiate between the associations and make a conclusion about the direction of 
causality. Additionally, diabetes is a known contributor to renal insufficiency and renal 
failure and, thus, is a risk factor for vitamin D deficiency due to decreased uptake and 
subsequent activation of vitamin D, and increased excretion in the urine (33). 
Cardiovascular Disease 
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VDRs and vitamin D metabolizing enzymes are highly prevalent in the 
cardiovascular system and the strong association between vitamin D status and 
cardiometabolic health is likely a strong factor behind the relationship between vitamin 
D status and overall mortality (6,62,63,89–94). Associations between cardiovascular 
disease (CVD) and both season and distance from the equator give rise to the possibility 
of low vitamin D status being an independent risk factor for CVD. There are vitamin D-
inducible genes which exert protective cardiometabolic effects, such as preventing 
atherosclerosis, suppressing renin and reducing myocardial damage (31,64,95). In vitro, 
calcitriol directly prevents foam cell production and low-density lipoprotein cholesterol  
(LDL) uptake by macrophages in diabetics, but the same was not observed in cells from 
non-diabetics (96). 
Epidemiological studies provide evidence to support the notion that low levels 
of calcidiol are associated with CVD risk factors and can predict the occurrence of 
cardiovascular events, including myocardial infarction and stroke (31,89–91,97). 
Although the number of observational studies with significant correlations is large, 
some of the results and explanations for underlying mechanisms are conflicting. A 
recent observational study investigated the association between vitamin D status and 
all-cause mortality, ischemic heart disease, and stroke in 9,146 Danish individuals; the 
investigators found a significant association between vitamin D and all-cause mortality 
but this was not explained by an association between vitamin D status and ischemic 
heart disease, or stroke (98). Wang et al. (99) observed 1739 subjects in the 
Framingham Offspring Study for just over 5 years and found a graded increase in the 
risk for events related to CVD, with an adjusted hazard ratio of 1.62 with the lowest 
vitamin D concentrations (<10 ng/mL) as compared to those with a slightly higher 
vitamin D status (>15 ng/mL). On the contrary, a prospective study by Alele et al. (100) 
on 936 diabetic veterans did not show a difference in incidence of myocardial 
infarction, congestive heart failure or overall mortality in those in the lowest compared 
to those in the highest quartile of vitamin D concentrations. Looking at specific CVD risk 
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factors, Martins et a l(91) used the third NHANES survey to look at associations 
between vitamin D status and specific cardiovascular risk factors and found a greater 
odds ratio for the prevalence of hypertension (1.30), type II diabetes (1.98), obesity 
(2.29), and high serum triglyceride levels (1.47) in subjects with vitamin D 
concentrations in the first compared to the fourth quartile. 
Randomized controlled trials confuse the conclusions about the direction of 
causality between vitamin D and CVD because the outcomes are diverse. While one 
showed modest improvements in risk factors, most did not (31,92,98,101). However, 
much of the intervention data reported on vitamin D status and mortality, and the risk 
factors, incidence and mortality from various conditions, often reported on these 
factors as secondary outcomes, and suffer from limitations such as poor compliance, 
low dosages, and populations who were not vitamin D deficient at the onset of the trial 
(31,101). A recent statement from the Endocrine Society recognized strong associations 
between vitamin D and musculoskeletal, cardiovascular, and metabolic disorders but 
called for additional large, long-term RCTs to clarify the preventative or treatment 
effects of vitamin D supplementation on these disorders (65). 
Hypertension 
The relationship between vitamin D deficiency and hypertension is well 
established and relates in part to the regulation of the renin-angiotensin system by 
calcitriol. This modulation occurs by way of suppressing renin gene expression via VDR, 
and low calcidiol concentrations may result in an up-regulation of the renin-angiotensin 
system (60,95,102–104). However, the differences in blood pressure between vitamin 
D deficient and sufficient groups is modest, at approximately 2 mmHg on average, and 
so improvements after vitamin D supplementation are difficult to show. Still, Pfeifer et 
al. (105) observed an added benefit of supplementing vitamin D plus calcium compared 
to calcium alone for a decreased systolic blood pressure. Additionally, exposure to UVB 
light and its concurrent stimulation of endogenous vitamin D production has been 
shown to moderate hypertension (106); the rapid production of nitric oxide (a known 
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modulator of blood pressure) by keratinocytes with UVB exposure may contribute to 
this finding (107).  Despite only modest improvements in blood pressure, the role 
functions of vitamin D for the suppression of renin is multifactorial in its implications 
for atherosclerosis; high concentrations of renin are an independent risk factor for 
morbidity and mortality related to cardiovascular disease and are  associated with the 
progression of thrombosis and left ventricular hypertrophy separately from its effects 
on blood pressure (108). 
Vitamin D and Serum Lipids 
Another potential contributor to the association between vitamin D and CVD 
could be related to serum lipid concentrations, a major independent risk factor for CVD. 
Association studies on vitamin D and serum lipids are plentiful, but the outcomes are 
mixed. Jorde et al. (109) observed an association between high vitamin D status and a 
favorable blood lipid profile in a cross-sectional study of 8,018 nonsmoking and 2,087 
smoking subjects in Norway; those in the highest quartile of vitamin D levels had a 6.0% 
and 18.5% difference in high-density lipoprotein cholesterol (HDL) and triglyceride (TG) 
concentrations, respectively, in nonsmokers. In the 1,762 non-smoking and 397 
smoking subjects in the cross-sectional, longitudinal component of the study there was 
an association between an increase in vitamin D over time and a decline in TG. 
Additionally, a recent study on 476 adults approximately 60 years of age showed a 
statistically significant correlation between vitamin D status and both diabetes and 
hypertension, but not for smoking and dyslipidemia (25). 
Observed relationships between vitamin D concentrations and LDL 
concentrations provide diverse conclusions. In the Jorde and Grimnes review (28), five 
of the seven papers reporting LDL found positive associations, only one being 
statistically significant, while three reported negative associations, with one being 
significant. Karhapää et al (110) observed an inverse association between 25OHD and 
LDL, but found no relationship between LDL and calcitriol. Evaluating the relationship 
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between vitamin D and TG is also difficult; there have been both positive and negative 
relationships observed (28). Because both LDL and HDL may both increase with 
improved vitamin D concentrations, looking at the ratio of TC:HDL is more appropriate 
in risk determination. In the four studies in the Jorde (28) review reporting a ratio, two 
out of three reported statistically significant negative associations with TC:LDL, and one 
reported a significant negative association between vitamin D and LDL:HDL. 
The associations between vitamin D concentrations and HDL appear to be the 
most straightforward. In a 2011 review by Jorde and Grimnes (28), all 20 publications 
included which reported the relationship between calcidiol concentrations and HDL 
observed a positive association between the two and half of these were statistically 
significant. However, the same research group recently observed a modest drop in HDL 
after vitamin D supplementation, contradicting their previous findings and evidence 
supporting a protective role of vitamin D on serum lipid parameters (88). Karhapää et al 
(110) observed an positive association between HDL and 1,25(OH)2D, but not for that 
and 25OHD.  
Intervention trials do not clarify the relationship between serum lipids; 
supplementation of vitamin D with calcium improves lipid profiles but studies 
supplementing vitamin D alone are divergent, and many have found no effect (111–
113). A meta-analysis by Wang et al. (114) observed a slight effect of vitamin D 
supplementation on LDL (3.23 mg/dL), but no effect on TC, HDL, or TG. A study by 
Zittermann et al. (115) displayed improvements in TG and tumor necrosis factor (TNF) 
with supplementation of 3,320 IU vitamin D/day compared to those receiving a 
placebo; the population was overweight women with low mean vitamin D levels at 
baseline (12 ng/mL) and the aim was to observe whether or not supplementation with 
vitamin D had an impact on adiposity, but no effect was found. In addition to 
improvements in TG and TNF, there was a worsening of LDL levels by 5.4%. A more 
recent study with overweight and obese women found significant improvements in HDL 
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(+2.7 mg/dL) but they also observed a slight worsening of both TC and LDL 
concentrations (116). 
Furthermore, a more recent study by Jorde et al. (88) found detrimental effects 
on metabolic parameters after supplementing 928 middle-aged subjects with 20,000-
40,000 IU/week vitamin D. Results from the intervention showed a slight decrease in 
HDL (3.08 mg/dL), an increase in HgA1c (0.04%) and an increase in high sensitivity C-
Reactive Protein (CRP) (0.07 mg/L). However, the results are from pooled data with a 
variable length of supplementation and dosage. Most importantly, albeit statistically 
significant, the results were not clinically meaningful and are unlikely to provide 
evidence against supplementing high doses of vitamin D. 
Cholesterol 
Background 
Cholesterol is a sterol molecule with crucial biological importance. It is a 
structural component of cell membranes, regulating fluidity and permeability, and is an 
essential precursor of the sex hormones and bile acids. Intermediates in the cholesterol 
biosynthesis pathway are also important for production of other molecules (e.g., 
ubiquinone), and other intermediates as well as cholesterol itself are used for 
posttranslational modifications of specific proteins. 
Metabolism 
 
Endogenous Cholesterol 
More than half of the cholesterol in the body is synthesized endogenously in the 
cytoplasm of cells from acetyl CoA, with the majority being produced in the liver. Two 
acetyl CoA molecules condense to form acetoacetyl CoA, and another acetyl CoA 
molecule is added by HMG-CoA synthase to form 3-Hydroxy-3-Methylglutaryl CoA 
(HMG-CoA). The final step, reduction of HMG-CoA to mevalonate by HMG-CoA 
20 
 
reductase, is the main regulation step in the synthesis of cholesterol; the activity of this 
enzyme is the target of statin therapy. HMG-CoA reductase is regulated by negative 
feedback from mevalonate and by the final cholesterol product by way of the sterol 
regulatory element binding proteins (SREBP) (117). 
SREBP1c is stimulated by insulin and feeding and induces enzymes in the fatty 
acid metabolism and TG synthesis pathway. SREBP2 is the primary responder to 
cholesterol concentrations in the blood and activates genes for the proteins involved in 
cholesterol biosynthesis and the LDL receptor (LDLR). High concentrations of 
cholesterol in the cell cause cholesterol to bind to proteins and prevent the cleavage of 
SREBPs, thus preventing the concomitant binding to sterol regulatory elements (SRE) in 
the nucleus, and subsequent activation of genes enhancing cholesterol synthesis and 
uptake (117).  
Dietary Cholesterol 
Cholesterol can also be obtained from animal products in the diet and this 
contributes approximately one third of that in the body. Dietary cholesterol is absorbed 
with dietary fat and fat-soluble vitamins in chylomicrons for transport to the lymphatic 
system and then to the general circulation at the thoracic duct. 
Transport 
In order to be transported in the aqueous circulation, cholesterol is carried via 
lipoproteins secreted by the intestine and liver. Apolipoproteins bind lipids, serve as 
cofactors for enzymes and are ligands for lipoprotein receptors. In addition, 
apolipoproteins are used to classify different types of lipoproteins in the circulation; 
Figure 1 shows the flow of cholesterol transport, the different lipoproteins, and their 
associated apolipoproteins (118).  
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Figure 1. Overview of cholesterol transport and lipoprotein metabolism. Reprinted from 
Olson, 1998. J Nutr. (118) 
 
The two primary lipoproteins are intestinal chylomicrons and hepatic very-low-
density lipoproteins (VLDL). Chylomicrons are secreted from the intestine 
postprandially and have the largest molecular weight and lipid content. They contain 
apolipoprotein B-48 (apo B-48) and pick up additional apolipoproteins (C and E) from 
circulating LDLs to become mature chylomicrons and VLDL. Lipoprotein lipase on 
capillary endothelia in the circulation and hepatic triglyceride lipase (HTGL) facilitates 
the loss of TG from chylomicrons and VLDL to form intermediate-density lipoproteins 
(IDL) and chylomicron remnants; this loss coincides with the loss of apo C. Uptake of IDL 
by the liver is mediated by apo E. Further loss of TG (and of apo E) results in the apo B-
containing LDL, which contain the highest proportion of cholesterol of all lipoproteins 
(118). 
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When considering serum lipid concentrations, LDL and HDL concentrations are 
considered in addition to total cholesterol, as these are the primary lipoproteins 
present in a fasted state. To put it simplistically, LDL cholesterol is considered 
detrimental to health due to its atherogenic properties, and HDL cholesterol is 
considered protective due to its function of returning cholesterol from the periphery 
back to the liver, and also due to its antioxidant properties (119). However, there are 
subtypes of each LDL and HDL cholesterol, which have varying degrees of risk 
associated with them (120). Small, dense LDL particle concentrations is a better 
indicator of risk than is total LDL. Similarly, small HDL particles do not yield the same 
protective properties as the larger HDL particles. The ratio of TC:HDL is better at 
predicting the amount of atherogenic subfractions than either TC or HDL alone, and is a 
better predictor of cardiac events (120,121). Concentrations of oxidized LDL and 
lipoprotein(a), a small, dense LDL particle with a second protein, apo(a), are associated 
with a less favorable lipid profile (119,122). 
LDL Receptor Family 
The LDL receptor family is a class of endocytotic transmembrane cell receptors 
that take up VLDL, IDL, and LDL in an apo E- and apo B-dependent manner. VLDL, IDL, 
LDL and chylomicron remnants are taken up by the liver via the LDL receptor (LDLR) and 
LDLR-related protein 1. Genetic disorders in LDL receptors are known to cause elevated 
LDL levels. Megalin is a newly recognized member of this family and is also the 
endocytotic receptor responsible for vitamin D reabsorption in the kidney (18,123). 
Relationship Between Vitamin D and Cardiovascular Disease Risk Factors 
Several factors may contribute to the relationship between vitamin D status and 
CVD risk and mortality; the incidence of obesity, amount of fat mass, adipocyte 
differentiation and proliferation, insulin secretion and sensitivity, blood pressure 
modulation, changes in blood lipids, and inhibition of atherogenesis are all associated 
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with vitamin D and can modulate CVD risk. Furthermore, vitamin D is inversely 
correlated with PTH levels, which have been linked to obesity, hypertension, heart 
failure, and increased mortality (28,29). 
As with obesity, it is important to consider whether or not the beneficial effects 
of vitamin D are due to the hormone itself or its association with calcium metabolism. 
Calcium intake modulates the effect of dietary fat on blood lipid values, which may also 
explain the role of calcium on an improved cholesterol profile (124). Calcium acts to 
form insoluble soaps with dietary fat, preventing its absorption, thus modulating the 
effect of high dietary fat on blood lipid concentrations (125). In addition, calcium may 
also bind bile acids, the loss of which increases the hepatic conversion of cholesterol to 
bile acids, reducing cholesterol (126). Supporting this was a study by Reid et al (125) 
which supplemented calcium or a placebo to 223 post-menopausal women with a 
mean age of 72 years; in the intervention group, 1 g calcium was taken daily for one 
year and fasting serum lipid concentrations (TC, HDL, LDL and TG) were obtained at 
baseline and 2, 6 and 12 months. They found no effect of calcium supplementation on 
TG, a significant 7% increase in HDL, a non-significant 6% decrease in LDL and a 
significant improvement in the LDL:HDL ratio. Effects of calcium on cholesterol levels 
are likely more pronounced than that on TG because of the contribution of bile acid 
synthesis in addition to the small amount of dietary fat lost in the feces. 
Vitamin D displays anti-inflammatory effects which could attribute to its 
beneficial effects on a variety of disease states associated with inflammation, including 
diabetes and cardiovascular disease. There is an inverse association between vitamin D 
and concentrations of CRP, a marker of inflammation and an independent risk factor 
for cardiovascular disease risk (29). Calcitriol acts to down-regulate pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF), interleukin-6 (IL-6), IL-1 and IL-8 
(127,128), and up-regulate the anti-inflammatory cytokine IL-10 (129). IL-6 is produced 
by both T-lymphocytes and adipocytes. Beilfuss and colleagues (127) observed an 
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improvement in IL-6 concentrations after one year of vitamin D supplementation in 
obese subjects, but did not observe improved markers of insulin sensitivity. 
IL-6 inhibits adiponectin, a peptide hormone with beneficial effects on 
atherogenesis, inflammation, glucose and fat metabolism, and obesity (127,130). 
Adiponectin is a cytokine released from adipocytes in relation to fat mass and is known 
to increase HDL levels while simultaneously having a beneficial role by lowing VLDL and 
LDL concentrations (131). Vitamin D levels are associated with increased adiponectin 
(130), and dietary interventions to improve vitamin D status coincided with an increase 
in adiponectin concentrations (132,133). Additionally, osteocalcin stimulates 
adiponectin expression and is a gene known to be up-regulated by vitamin D. The effect 
of vitamin D on adiponectin directly and through the down-regulation of IL-6 and/or 
up-regulation of osteocalcin may provide a mechanism by which vitamin D benefits 
CVD and CVD risk factors. 
Inflammatory cytokines induce the action of endothelial 1αOHase and calcitriol 
modulates endothelial cell adhesion (134), modulating atherogenesis. Both endothelial 
cells and vascular smooth muscle cells contain VDR and calcitriol regulates many 
aspects of vascular smooth muscle cell function, such as contraction, growth and 
migration, and coronary calcification. Additionally, endothelial cells in the vasculature 
contain the 1αOHase enzyme, thus are able to produce active calcitriol (134). VDR 
deficient mice display accelerated atherosclerosis due to the effects on the renin-
angiotensin system and macrophage vitamin D receptors (135). Vitamin D deficiency is 
associated with arterial stiffness and endothelial dysfunction (133) and 
supplementation with vitamin D in humans improves arterial compliance (84,133). 
The mechanisms driving the association with vitamin D deficiency and both CVD 
risk and mortality are still being elucidated with intervention studies. Boer et al. (136) 
looked at vitamin D deficiency and coronary artery calcification in 1,370 participants in 
the Multi-Ethnic Study of Atherosclerosis and determined that lower vitamin D 
concentraations were not associated with coronary artery calcification, but were 
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associated with an increased risk for its development after adjusting for co-morbidities 
such as age, physical activity, CRP, season, smoking, BMI, diabetes, and serum lipids. A 
recent double-blind study supplemented 100 diabetic patients with 5,000 IU/day or a 
placebo for 12 weeks and observed no change in vascular function as evidenced by 
flow-mediated dilation and circulating levels of endothelial progenitor cells, nor did 
they see differences in high sensitivity CRP, oxidative stress markets, LDL, HDL, or 
HgA1C (137). Beilfuss et al. (127) observed a slight worsening in the high sensitivity CRP 
test in overweight and obese subjects after one year of supplementation of 20,000 or 
40,000 IU/week of vitamin D. 
Kidney function is strongly associated with vitamin D status, as it is the primary 
site for activation of calcidiol to the physiologically active calcitriol. Megalin and cubilin 
are necessary for filtration of the vitamin D-DBP complex in the kidney and renal 
insufficiency instigates vitamin D deficiency due to urinary losses and the prevention of 
subsequent activation (18,33). Megalin is also a member of the LDL receptor family and 
has a high affinity for the apolipoprotein B-containing lipoproteins. Apolipoprotein A-I 
and thus HDL, is a ligand for cubilin (123,138). Therefore, megalin and cubilin are 
important for vitamin D uptake and activation and can also facilitate the removal of 
lipoproteins. In turn, megalin expression is regulated by vitamin D (139).  
Some researchers have observed an increase in calcidiol concentrations with 
statin use and this is an important consideration when making conclusions on vitamin D 
status and serum lipids. Effects of statin therapy on vitamin D seems to differ between 
statin types (140). Atorvastatin has been shown to increase calcidiol concentrations 
(141), but an opposite effect of Atorvastatin decreasing calcidiol concentrations has 
been observed (142). Until the exact relationship is determined, it is important to be 
aware of a potential connection between statin therapy and vitamin D concentrations. 
Finally, it is important to consider whether vitamin D status is a cause or a 
marker for CVD. The direction of the relationship is unclear because of the association 
between vitamin D status and an overall healthy lifestyle. Calcidiol concentrations are 
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associated with being outdoors and being physically active and weight loss is associated 
with increased calcidiol levels (31,143). 
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Abstract 
 Background. One explanation for the relationship between vitamin D and 
cardiovascular disease (CVD) mortality could be related to altered serum lipids. This 
study aimed to clarify the association between 25OHD and serum lipid concentrations 
in healthy, older adults. 
 Methods. Serum lipid panels and 25OHD concentrations were obtained on 190 
adults (median age 67 years) after a 12-hour overnight fast. 25OHD was measured by 
the DiaSorin Liaison system. Subjects were stratified by 25OHD concentrations: <20.0 
ng/mL, 20.0-29.9 ng/mL, 30.0-39.9 ng/mL and ≥40 ng/mL. One-way ANOVA was used to 
observe unadjusted differences and Student’s t-tests were used to determine 
differences between groups. Multiple regression analyses were performed to 
determine the ability of 25OHD to predict serum lipid concentrations when accounting 
for BMI, sex, age, and statin use. Stepwise regression analyses were used to establish 
the best prediction model for each outcome. 
 Results. There was a significant relationship between 25OHD and BMI (p<0.001), 
glucose (p=0.042), TG (p=0.020), TC (p<0.001), LDL (p<0.001) and the TC:HDL ratio 
(p<0.001), but not for blood pressure, HDL, or TG:HDL. When comparing subjects with 
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25OHD  ≥40.0 ng/mL to those with <20 ng/mL, those in the former group had a 
significantly lower BMI (26.1 ± 0.7 and 29.9 ± 0.8 kg/m2), TG (100.9 ± 7.8 and 130.4 ± 
9.5 mg/dL), TC (182.7 ± 5.2 and 217.4 ± 6.3 mg/dL), LDL (100.3 ± 4.5 and 131.2 ± 5.4 
mg/dL), higher calcium (9.67 ± 0.05 and 9.50 ± 0.06 mg/dL) concentrations, and had 
significantly lower TC:HDL  (3.09 ± 0.15 and 4.15 ± 0.08) and TG:HDL (1.79 ± 0.22 and 
2.56 ± 0.27) ratios.  
 When adjusting for confounders, the relationship between 25OHD and TC 
(p<0.001) and LDL (p<0.001) remained significant, but that between TC:HDL and 
TG:HDL did not. When a stepwise regression analysis was performed to determine the 
best model for predicting serum lipid parameters, each 1 ng/mL increase in 25OHD 
predicted a statistically significant 0.672 mg/dL decline in TC (p<0.001) and 0.555 mg/dL 
decline in LDL (p<0.001). 
 Conclusion. 25OHD status is associated with favorable concentrations of TG, TC, 
LDL and lipid ratios in older adults. When adjusting for confounders, this relationship 
remains for TC and LDL. Altered lipid metabolism may help explain the association 
between vitamin D and CVD mortality. 
Introduction 
Vitamin D is a fat-soluble vitamin that functions as a steroid hormone and can 
be obtained from the diet or synthesized endogenously with exposure to ultra-violet B 
(UVB) light. It is found in the diet naturally (e.g. fatty fish) artificially in fortified food 
products (e.g. dairy), or obtained in a supplement form. Supplements may be in the 
plan- or fungal-derived form, vitamin D2 (ergocalciferol) or vitamin D3 (cholecalciferol). 
Both forms are effective at increasing serum concentrations of 25OHD, the storage 
form of vitamin D, and will be referred to simultaneously as vitamin D (1,2). 
Endogenous biosynthesis of vitamin D from 7-dehydrocholesterol occurs in the dermis 
and epidermis with exposure to UVB light in the optimum wavelength (between 290-
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320 nanometers) and thus is dependent on season, latitude, the amount of skin 
exposed, skin pigmentation, sunscreen use, and age (3,4). 
Vitamin D and its metabolites are transported to the liver via vitamin D binding 
protein (DBP), where the first hydroxylation to 25OHD, or calcidiol, occurs primarily by 
way of the CYP27A1 enzyme. 25OHD is the most commonly used and most effective 
measurement of vitamin D status (5). The second hydroxylation to the physiologically 
active 1,25(OH)2D, or calcitriol, occurs primarily in the kidney by CYP27B1, another 
cytochrome P450 superfamily member (6). This activation step is reliant on the uptake 
of the calcidiol-VBP complex in the kidney by the endocytotic receptor proteins megalin 
and cubilin, for which DBP is a high-affinity ligand (7,8). 1,25(OH)2D has high affinity for 
the vitamin D receptor (VDR) and the VDR-calcitriol complex forms a heterodimer with 
a retinoic X receptor (RXR). Together, they bind to the vitamin D response element 
(VDRE), present in the promoter region of many genes, and acts as a ligand-activated 
transcription factor to activate or repress gene expression, such as that for calcium 
channel receptors in the small intestine. CYP27B1 is under tight regulation by 
parathyroid hormone (PTH), calcium, phosphate, calcitonin, and fibroblast growth 
factor 23, in addition to negative feedback by the 1,25(OH)2D end product. 1,25(OH)2D 
concentrations are directly related to calcium and phosphorus homeostasis and are not 
a good indicator of vitamin D status, as concentrations are maintained or even elevated 
when vitamin D stores are low. 
VDR is found quite ubiquitously throughout the body and extrarenal tissues 
express the gene for CYP27B1 as well as those for megalin and cubilin. Presence of the 
cellular machinery necessary for uptake and subsequent activation of vitamin D outside 
of the kidney alludes to a role of vitamin D in paracrine and autocrine functions (7–10). 
It is no surprise that several of the tissues known to express VDR, CYP27B1, megalin, 
and cubilin are those implicated in disease states associated with vitamin D deficiency; 
these include the brain, prostate, breast, vasculature, and immune cells (8–13). 
Consequently, several large, epidemiological studies have shown associations between 
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low vitamin D status and increased risk for premature mortality from all-causes, and 
specifically for cardiovascular disease, certain types of cancer, and respiratory illnesses 
(12,14,15).  
There are several indirect and direct relationships between vitamin D status and 
cardiovascular disease and the strong associations between cardiometabolic health and 
vitamin D status likely contribute to the higher risk of all-cause mortality in vitamin D 
deficient individuals (16). Vitamin D is known to down-regulate renin, which is well-
known for its implication in hypertension, but is also an independent risk factor for 
morbidity and mortality (17,18). Renin is associated with thrombus progression and 
left-ventricular hypertrophy independently of blood pressure (19). In addition, 25OHD 
is lower in those with obesity and diabetes, and vitamin D has known anti-inflammatory 
effects, all of which could modulate cardiometabolic health (15,20). PTH levels are 
directly affected by vitamin D status and have also been linked to obesity, 
hypertension, heart failure, and increased mortality (21). 
There is no doubt that the relationship between cardiovascular disease and 
vitamin D status is multifactorial, but one potential explanation could be the affiliation 
of altered serum lipid concentrations with vitamin D status. Others have found 
associations between storage concentrations of vitamin D and serum lipids, but the 
outcomes have been divergent (22–25). The purpose of this study was to determine 
whether or not an association was present between 25OHD and dyslipidemia in an 
otherwise healthy group of older adults. Clarification of this relationship can aid in the 
appropriate target population(s) and study designs for intervention studies aimed to 
elucidate the relationship between dyslipidemia and vitamin D status. 
44 
 
Methods 
Subjects 
 Subjects were males and females at least 60 years of age recruited from the 
Ames, Iowa area to be screened for an intervention study designed to look at 
nutritional interventions for age-related muscular function and strength loss (see 
Appendix A for recruitment letter). Informed consent was obtained (see Appendix B) 
after an explanation of what the screening appointment entailed as well as details of 
the study if the respondent were to qualify. Subjects were free of liver and kidney 
disease and of chronic disease that affects calcium or bone metabolism, not classified 
as morbidly obese, and free of osteoporosis or other serious medical illnesses. 
Participants were excluded if they had uncontrolled hypertension, were insulin-
dependent, had surgery within the last six weeks, or were taking high doses of vitamin 
D. 
Measurements 
Anthropometric data (height, weight, blood pressure, and heart rate) and a 
blood sample by venipuncture were obtained after a 12-hour overnight fast. Fasting 
was verified by the phlebotomist and if a 12-hour fast was not confirmed, 
measurements of triglyceride and glucose concentrations were not considered. Height, 
weight, blood pressure and heart rate were measured in duplicate and means were 
reported. Blood pressure was measured after subjects were sitting for several minutes 
with five minutes between the two measurements. Medical history information, 
demographic forms, a list of medications used, the Clinical Research Health Form, the 
Clinical Research Feeling Form, and the SF-36 Health Survey were completed. 
Serum 25OHD were measured in duplicate using the DiaSorin Liaison system, 
with intra-assay coefficient of variance 5.4% (Heartland Assays, Ames, IA), and the 
average is reported. This assay is a direct competitive chemiluminescence 
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immunoassay for quantitative determination of 25OHD concentrations in serum, which 
has been validated as an accurate and useful tool for determining vitamin D status 
(26,27). Blood chemical panels, which included determination of serum total 
cholesterol, high-density lipoprotein cholesterol concentrations (HDL), triglyceride 
concentrations (TG), and plasma glucose concentrations, as determined by enzymatic 
methods, were conducted by Laboratory Corporation of America® (Cranford, NJ). Low-
density lipoprotein cholesterol concentrations (LDL) were calculated using the 
Friedewald equation: LDL = TC – HDL – TG*(0.2).   
Statistical Analysis 
First, subjects were stratified into four groups by 25OHD concentrations: <20.0 
ng/mL, 20.0-29.9 ng/mL, 30.0-39.9 ng/mL, and ≥40 ng/mL. Means ± standard errors for 
all variables were calculated for each group and one-way analysis of variance (ANOVA) 
and Student’s t-tests were used to identify significant differences between groups. 
Results from ANOVA were used to identify confounding variables, which were 
accounted for in the regression model. 
Second, multiple regression analyses were performed to determine the ability 
of 25OHD concentration as a continuous variable to predict TC, HDL and TG 
concentrations and the TC:HDL ratio. Models were constructed to determine the 
contribution of vitamin D (constant independent variable) for predicting serum lipid 
parameters (dependent variable) after accounting for covariates. The first model used a 
multiple regression analysis for each lipid parameter while accounting for BMI, sex and 
statin use. The second model used a forward stepwise regression approach to 
determine the best prediction model using available data; variables were included in 
the model if the estimate for prediction was significant at p < 0.25. Histograms of 
variable distributions and residual plots of outcome variables were visually analyzed for 
appropriateness of models. Outcome variables that were not normally distributed were 
transformed for regression analyses.   
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Analyses were performed using JMP® 10 for Windows and significance was set 
at p < 0.05. 
Results 
Between January 2012 and April 2013, 190 subjects were screened in Ames, 
Iowa (latitude 42° N). Females comprised 83/190 (43.7%), 187/190 (98.4%) were 
Caucasian, mean BMI was 28.3 ± 0.3 kg/m2, and 66/190 (34.7%) were prescribed statin 
therapy. Age of subjects ranged from 60-89 years with median age of 67. There were 
no differences between men and women for any variable measured except systolic 
blood pressure (BP), which was significantly lower in women (132 ± 2 mmHg) than in 
men (138 ± 2 mmHg).   
Subject characteristics are reported in relation to serum 25OHD concentration 
ranges (<20, 20-29.9, 30-39.9, and ≥40 ng/mL) in Table 1. The number of subjects in 
each range of 25OHD levels, <20, 20-29.9, 30-39.9, and ≥40 ng/mL, was N=31, 59, 55 
and 45, respectively. The number of subjects who were fasted at the time of the blood 
draw and, consequently, were included in the analysis of TG and glucose in addition to 
serum cholesterol concentrations, was 31, 58, 55 and 43 for each range of 25OHD 
concentration: <20, 20-29.9, 30-39.9, and ≥40 ng/mL. TG concentrations were normal 
log transformed to fit a normal distribution before regression analyses. 
There was a statistically significant relationship between 25OHD and sex 
(p=0.024), age (p=0.006), BMI (p<0.001), glucose (p=0.042), TG (p=0.020), TC (p<0.001), 
LDL (p<0.001) and the TC:HDL ratio (p<0.001), but not for calcium, systolic BP, diastolic 
BP, HDL, TG:HDL, nor in proportions using statins. When comparing subjects with the 
highest (≥40.0 ng/mL) to the lowest (<20 ng/mL) concentrations of 25OHD, those in the 
highest range were older (69.7 ± 1.1 and 65.9  ± 1.3 years old), had a lower BMI (26.1 ± 
0.7 and 29.9 ± 0.8 kg/m2), TG (100.9 ± 7.8 and 130.4 ± 9.5 mg/dL), TC (182.7 ± 5.2 and 
217.4 ± 6.3 mg/dL), LDL (100.3 ± 4.5 and 131.2 ± 5.4 mg/dL), and higher calcium (9.67 ± 
0.05 and 9.50 ± 0.06 mg/dL) concentrations, and had lower TC:HDL  (3.09 ± 0.15 and 
4.15 ± 0.08) and TG:HDL (1.79 ± 0.22 and 2.56 ± 0.27) ratios. 
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There was not a significant difference between those with the highest (≥40 
ng/mL) and the lowest (<20 ng/mL) concentrations of 25OHD for HDL, diastolic BP, 
systolic BP, and plasma glucose. Additionally, there was no difference between groups 
for the number of individuals with elevated creatinine levels (classified as >1.0 mg/dL 
for women, >1.2 mg/dL for men), or the ratio of blood urea nitrogen to creatinine 
(BUN:Cr), which may suggest  renal dysfunction (data not shown). 
 After accounting for BMI, sex, age and statin use, every one-unit ng/mL increase 
in 25OHD was associated with an average 0.673 mg/dL decline in TC (p<0.001), and an 
average 0.521 mg/dL decline in LDL (p=0.003) (Table 2). There was a non-significant 
trend toward a lower TC:HDL ratio with a higher 25OHD (p=0.054). 25OHD status was 
not a statistically significant predictor of TG, TC:HDL nor TG:HDL, adjusting for BMI, sex, 
and statin use. When a stepwise regression analysis was performed to determine the 
best model for predicting serum lipid parameters, a 1 ng/mL increase in 25OHD was 
associated with a statistically significant mean 0.672 mg/dL decline in TC (p<0.001) and 
0.555 mg/dL decline in LDL (p<0.001) (Table 3). 25OHD was not a statistically significant 
predictor for TG, HDL, TC:HDL or TG:HDL, as evidenced by its exclusion from the 
prediction model that was deemed most appropriate by a stepwise regression analysis.  
 Significant predictors for serum lipid parameters as determined by stepwise 
regression analysis (with the regression coefficient for the model) were as follows: 
systolic BP, BMI, calcium, glucose, and age for TG (R2= 0.238), 25OHD, sex, diastolic BP, 
calcium, and statin use for TC (R2= 0.341), sex, BMI, and glucose for HDL (R2= 0.266), 
vitamin D, sex, diastolic BP, calcium, and statin use for LDL (R2= 0.293), glucose, 
diastolic BP, sex, BMI, and statin use for TC:HDL (R2= 0.181), and sex, glucose, calcium, 
and BMI for TG:HDL (R2= 0.253). 
Discussion 
This study aimed to determine whether or not vitamin D status was associated 
with serum lipid concentrations in a healthy older adult population. Our data showed a 
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significant association between vitamin D status and a favorable lipid profile, with a 
decrease in TG, TC, LDL, and TC:HDL ratio with increasing levels of vitamin D. We also 
observed a significant association between 25OHD concentrations and differences in 
gender, BMI, calcium, and glucose concentrations. Because several of the variables 
considered are interrelated with one another in addition to being associated with 
vitamin D, we used regression analyses to account for potential covariates. After 
adjustment for covariates using a pre-determined model for all outcome variables and 
also using a stepwise regression analysis to determine the best prediction model, we 
determined that 25OHD could effectively predict serum concentrations for TC and LDL 
cholesterol.  
Ponda et al’s (24) analysis of vitamin D levels and serum lipids in a large clinical 
laboratory database found modest yet favorable differences between 25OHD levels 
and TC, LDL, HDL, and TG. Jorde et al (22) found significant and favorable differences 
between HDL and TG for those in the highest quartile of vitamin D status. A review by 
the same group concluded that HDL and vitamin D had the most straightforward 
relationship; 20 included publications reported a positive association between vitamin 
D levels and HDL, with half of these relationships being statistically significant (28). We 
observed a trend of higher HDL in those with better vitamin D status but the small 
sample size did not allow for the power to see potentially statistically significant 
differences in this parameter.   
Results on associations between 25OHD and LDL are divergent. Jorde et al. (22) 
observed a detrimental, positive association between vitamin D status and the 
atherogenic LDL cholesterol. In contrast, Karhapää et al. (29) observed an inverse 
relationship between the two variables in an all-male population of a similar age. Our 
data support the prevalence of a beneficial inverse association between 25OHD and 
LDL concentrations.  In addition to finding statistically significant differences between 
those with the highest compared to the lowest concentrations of 25OHD, we found 
clinically significant differences large enough to modulate cardiovascular disease risk. 
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Table 4 displays the optimum ranges for serum lipids as defined by the National 
Cholesterol Education Program (30). Those with vitamin D concentrations ≥40 ng/mL 
had an average TC in the “Desirable” range, as compared to a mean TC level 19% higher 
and classified as “Borderline High” in those with the lowest 25OHD concentrations. 
Similarly for LDL cholesterol, having a vitamin D level ≥40 ng/mL was associated with a 
more favorable interpretation of LDL values. 
Interpreting the ratio of TC:HDL and TG:HDL is more enlightening than each 
parameter alone when determining cardiometabolic risk. TC >200 mg/dL is a risk factor 
for cardiac events, but if a high proportion is made up of the protective HDL cholesterol 
risk is lower than if the elevation is due primarily to increased amounts of the 
atherogenic LDL cholesterol (30). Further, subtypes of the lipoproteins are better at 
clarifying the risk of atherogenesis, as the smaller lipoprotein LDL and larger HDL 
subfractions are thought to be more atherogenic (31). Nuclear magnetic resonance 
(NMR) spectroscopy is a method used to differentiate between the lipoprotein 
particles, but it is time-consuming and expensive. The ratio of TC:HDL is better at 
predicting the amount of atherogenic subfractions than either TC or HDL alone, and is a 
better predictor of cardiac events (31,32). We observed a better TC:HDL ratio in those 
with higher vitamin D levels, but this relationship was lost after accounting for 
covariates. 
The ratio of TG:HDL is another useful tool for identifying CVD risk, and a higher 
TG:HDL is associated with the concentration of the small, dense, atherogenic LDL 
particles (33); this is due to the presence of a large amount of TG-rich VLDL, which 
generate small, dense LDL particles after lipolysis. A high TG:HDL is an indicator of 
altered glucose and lipid metabolism and is associated with insulin resistance and beta 
cell dysfunction (33–35). As a consequence, diabetics are at an increased risk of high 
TG:HDL and are known to have lower vitamin D stores [33, 34] . Similarly, vitamin D is 
known to have a beneficial effect on insulin sensitivity and pancreatic beta cell function 
(36). We observed a higher fasting glucose concentration and a less favorable TG:HDL 
50 
 
ratio in those with higher vitamin D concentrations, but neither relationship was 
maintained after accounting for other variables. 
One study showed that the relationship between TG:HDL and cardiac events 
was nonsignificant when accounting for kidney dysfunction in Type II diabetics, alluding 
to kidney health as an important mediator in this association (37). Kidney function is 
also strongly associated with vitamin D status, as it is the primary site for activation of 
calcidiol to the physiologically active calcitriol. Megalin and cubilin are necessary for 
filtration of the vitamin D-DBP complex in the kidney and renal insufficiency instigates 
vitamin D deficiency due to urinary losses and the prevention of subsequent activation 
(7,38). Megalin is also a member of the LDL receptor family and has a high affinity for 
the apolipoprotein B-containing lipoproteins. Apolipoprotein A-I, thus HDL, is a ligand 
for cubilin.(8,39) Therefore, megalin and cubilin are important for vitamin D uptake and 
activation and have the ability to remove lipoproteins from the circulation.  In turn, 
megalin expression is regulated by vitamin D (40). This relationship may provide insight 
to a potential mechanism contributing to the relationship between vitamin D and 
serum lipid concentrations. 
Another potential mechanism underlying changes in lipid profile and vitamin D 
status is that of vitamin D, serum lipids and adiponectin. Adiponectin is a cytokine 
released from adipocytes in relation to fat mass and is known to increase HDL levels 
while simultaneously having a beneficial role by lowing VLDL and LDL concentrations 
(41). Vitamin D levels are associated with increased adiponectin (42), and dietary 
interventions designed to improve vitamin D status coincided with an increase in 
adiponectin concentrations (43). Vitamin D status also has a negative association with 
arterial compliance and endothelial dysfunction (44). Supplementation with vitamin D 
improved Central Aortic Augmentation Index scores in addition to adiponectin 
concentrations independently of glucose control in diabetics (45).  
 Our study was limited by having a small convenience sample and the inability to 
make conclusions about cause-and-effect relationships between vitamin D status and 
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serum lipids due to a correlational approach. Additionally, this study was done as a 
secondary analysis of screening subjects for a randomized-controlled trial to look at 
nutritional interventions for the prevention of sarcopenia, so it was not designed 
specifically to look at this relationship. Additionally, we were unable to account for 
potential endogenous vitamin D synthesis. Future research should be conducted to 
determine whether or not supplementation with vitamin D has an impact on serum 
lipid parameters and to try to elucidate the mechanisms behind this relationship.  
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Table 1. Age, gender, BMI, blood pressure, glucose, serum lipids, and statin use in relation to serum 
vitamin D concentration levels in all subjects. 
 Serum 25OHD Concentrations1  
 <20 
ng/mL 
20.0-29.9 
ng/mL 
30.0-39.9 
ng/mL 
≥40.0  
ng/mL 
P-value2 
 N=31 N=59 N=55 N=45  
      
Sex (% female) 38.7 30.5 58.2 46.7 0.024* 
Age (years) 65.9a ± 1.3 68.2a,b ± 0.9 68.9
a,b ± 1.0 69.7b ± 1.1 0.006* 
BMI (kg/m2) 29.9a ± 0.8 29.4a ± 0.6 28.2a ± 0.6 26.1b ± 0.7 <0.001* 
Statins (% using) 22.6 33.9 36.4 42.2 0.360 
      
Calcium (mg/dL) 9.50a ± 0.06 9.58a,b ± 0.04 9.56a,b ± 0.05 9.67b ± 0.05 0.143 
Systolic BP (mmHg) 133.4 ± 3.2 135.9 ± 2.3 136.5 ± 2.4 135.2 ± 2.7 0.559 
Diastolic BP (mmHg) 74.2 ± 1.9 77.6 ± 1.4 74.0 ± 1.4 74.5 ± 1.6 0.342 
Glucose (mg/dL)3 95.1 ± 2.4 97.3 ± 1.7 93.7 ± 1.8 92.7 ± 2.0 0.042* 
      
TG (mg/dL)3 130.4a ± 9.5 119.2a,b ± 6.9 115.5a,b ± 7.2 100.9b ± 7.8 0.020* 
TC (mg/dL) 217.4a ± 6.3 192.4b,c ± 4.6 197.8b ± 4.7 182.7c ± 5.2 <0.001* 
HDL (mg/dL) 57.2 ± 3.2 58.4
 ± 2.3 64.0 ± 2.4 62.1 ± 2.6 0.243 
LDL (mg/dL) 131.2a ± 5.4 109.7b ± 3.9 110.4b ± 4.04 100.3b ± 4.5 <0.001* 
TC:HDL ratio 4.15a ± 0.18 3.45b ± 0.13 3.33
b ± 0.13 3.09b ± 0.15 <0.001* 
TG:HDL ratio 2.56a ± 0.27 2.26a,b ± 0.19 2.11a,b ± 0.20 1.79b ± 0.22 0.052 
Abbreviations: BMI, body mass index; BP, blood pressure; TG, triglyceride; TC, total cholesterol; HDL, 
high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol. 
1Values listed are mean ± standard error for each concentration of 25OHD. Student’s t-tests were used 
to compare means for quantitative variables; values with different letters are statistically different from 
one another. 
2One-way analysis of variance to determine associations for quantitative variables and the Pearson chi-
square test was used to test differences between group proportions for categorical variables. 
3Subjects who had not fasted when the blood sample was obtained were excluded from the  analysis of 
glucose and TG concentrations. N for TG and glucose in each level of 25OHD were 31, 58, 55, and 43. 
*Indicates statistical significance at p <0.05 
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Table 2. Results of multiple regression analyses to determine the 
ability of vitamin D status to predict serum lipid concentrations when 
adjusting for BMI, sex and statin use. 
 β1 of vitamin D 
± Std Error 
p for 
25OHD 
R2 of 
model 
    
TG (mg/dL) -0.418 ± 0.310 0.180 0.132 
TC (mg/dL) -0.673 ± 0.194 <0.001* 0.310 
HDL-C (mg/dL) -0.024 ± 0.098 0.809* 0.256 
LDL-C (mg/dL) -0.521 ± 0.171 0.003* 0.272 
TC:HDL ratio -0.012 ± 0.006 0.054 0.179 
TG:HDL ratio -0.008 ± 0.009 0.324 0.172 
Abbreviations: BMI, body mass index; BP, blood pressure; TG, 
triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein 
cholesterol. 
1Change in parameter per 1 ng/mL increase of 25OHD; adjusted for 
sex, BMI and statin use. 
*Indicates statistical significance at p <0.05 
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Table 3. Results of a stepwise regression analysis to determine the 
ability of vitamin D status to predict serum lipid concentrations 
within the best prediction model. 
 β1 of vitamin D 
± Std Error 
p for 
25OHD 
R2 of 
model 
    
TG3 (mg/dL) -0.420 ± 0.293 0.154 0.238 
TC4 (mg/dL) -0.672 ± 0.180 <0.001* 0.341 
HDL-C5 (mg/dL) -0.056 ± 0.096 0.559 0.266 
LDL-C6 (mg/dL) -0.555 ± 0.159 <0.001* 0.293 
TC:HDL7 ratio -0.010 ± 0.006 0.104 0.181 
TG:HDL8 ratio -0.004 ± 0.008 0.576 0.253 
Abbreviations: BMI, body mass index; BP, blood pressure; TG, 
triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein 
cholesterol. 
1Change in parameter per 1 ng/mL increase of 25OHD; best 
prediction model as determined by inclusion of variables with a p-
value threshold <0.25. 
3Adjusted for systolic BP, BMI, calcium and glucose and age 
4Adjusted for sex, diastolic BP, calcium, and statins 
5Adjusted for sex, BMI, and glucose 
6Adjusted for sex, diastolic BP and statin use 
7Adjusted for glucose, diastolic BP, sex, BMI and statin use 
8Adjusted for sex, glucose, calcium, and BMI 
*Indicates statistical significance at p <0.05 
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Table 4. Optimum ranges for blood lipid parameters 
according to the National Cholesterol Education 
Program [30]. 
 Interpretation  
of Values 
TG (mg/dL)  
<150 Normal 
150-199 Borderline High 
200-499 High 
≥500 Very High 
TC (mg/dL)  
<200 Desirable 
200-239 Borderline High 
≥240 High 
HDL-C (mg/dL)  
<40 Risk Factor for CVD 
40-60 Normal 
≥60 Protective 
LDL-C (mg/dL)  
<100 Optimal 
100-1291 Near Optimal 
130-159 Borderline High 
160-189 High 
≥190 Very High 
1Not considered hazardous unless other CVD risk 
factors are present 
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Figure 1. Mean triglyceride levels across vitamin D concentration 
ranges. Different letters indicate statistically significant differences 
between groups and error bars indicate ±1 standard error. 
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Figure 2. Mean Total Cholesterol levels across vitamin D concentration 
ranges. Different letters indicate statistically significant differences 
between groups and error bars indicate ±1 standard error. 
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Figure 3. Mean HDL Cholesterol levels across vitamin D concentration 
ranges. Different letters indicate statistically significant differences 
between groups and error bars indicate ±1 standard error. 
Figure 4. Mean LDL Cholesterol levels across vitamin D concentration 
ranges. Different letters indicate statistically significant differences 
between groups and error bars indicate ±1 standard error. 
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Figure 5. Mean TG:HDL ratio across vitamin D concentration ranges. 
Different letters indicate statistically significant differences between 
groups and error bars indicate ±1 standard error. 
Figure 6. Mean TC:HDL ratio across vitamin D concentration ranges. 
Different letters indicate statistically significant differences between 
groups and error bars indicate ±1 standard error. 
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